Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer’s disease. A prescription medicine, Kisunla 350mg/20mL intravenous injection is indicated to be used every four weeks in patients with early symptomatic Alzheimer’s. The gold standard of business intelligence.
Patients with mild cognitive impairment (MCI) and mild dementia, having confirmed amyloid pathology, are eligible to receive the treatment. The approval by Japanese authorities is based on the double-blind, placebo-controlled Phase III TRAILBLAZER-ALZ 2 clinical study. The trial assessed the safety and efficacy of donanemab in 1,736 participants with early symptomatic Alzheimer’s across eight countries.
Findings indicated that patients at the earliest stages of the disease responded best to Kisunla treatment. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Patients were monitored over 18 months and divided into two cohorts: those less advanced in their disease progression, and the overall population, which included individuals with higher levels of tau protein.
Kisun.
